
LAS VEGAS — At the Eyecelerator@ASCRS meeting, Ben Bergo, president and CEO of Visus Therapeutics, discusses Brimochol (carbachol and brimonidine tartrate), the company’s lead candidate for presbyopia.
LAS VEGAS — At the Eyecelerator@ASCRS meeting, Ben Bergo, president and CEO of Visus Therapeutics, discusses Brimochol (carbachol and brimonidine tartrate), the company’s lead candidate for presbyopia.